Estrella Immunopharma, Inc. (NASDAQ:ESLA) Short Interest Down 28.3% in September

Estrella Immunopharma, Inc. (NASDAQ:ESLA) was the target of a significant drop in short interest in September. As of September 30th, there was short interest totaling 26,300 shares, a drop of 28.3% from the September 15th total of 36,700 shares. Currently, 0.3% of the shares of the stock are sold short. Based on an average daily volume of 56,900 shares, the short-interest ratio is presently 0.5 days. Based on an average daily volume of 56,900 shares, the short-interest ratio is presently 0.5 days. Currently, 0.3% of the shares of the stock are sold short.

Estrella Immunopharma Price Performance

Shares of ESLA opened at $2.33 on Friday. Estrella Immunopharma has a 1-year low of $0.63 and a 1-year high of $2.55. The stock has a market cap of $86.37 million, a PE ratio of -8.96 and a beta of 0.39. The firm has a 50-day simple moving average of $1.24 and a two-hundred day simple moving average of $1.04.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on ESLA shares. D. Boral Capital reaffirmed a “buy” rating and set a $16.00 price objective on shares of Estrella Immunopharma in a report on Tuesday, August 12th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Estrella Immunopharma in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $16.00.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.